|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Expert Consensus on Clinical Diagnostic Criteria for Fatal Familial Insomnia显示文摘 | Li-Yong Wu Shu-Qin Zhan Zhao-Yang Huang Bin Zhang Tao Wang Chun-Feng Liu Hui Lu Xiao-Ping Dong Zhi-Ying Wu Jie-Wen Zhang Ji-Hui Zhang Zhong-Xin Zhao Fang Han Yah Huang Jun Lu Serge Gauthier Jian-Ping Jia Yu-Ping Wang | 2018 | Chinese Medical Journal2018,,13: | 10 |
| 2 | Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria显示文摘 | Bruno Dubois Howard H Feldman Claudia Jacova Harald Hampel José Luis Molinuevo Kaj Blennow Steven T DeKosky Serge Gauthier Dennis Selkoe Randall Bateman Stefano Cappa Sebastian Crutch Sebastiaan Engelborghs Giovanni B Frisoni Nick C Fox Douglas Galasko Ma | 2014 | Lancet Neurology2014,,6: | 7 |
| 3 | Cerebrospinal fluid phosphorylated tau,visinin-like protein-1,and chitinase-3-like protein 1 in mild cognitive impairment and Alzheimer’s disease显示文摘Background:Visinin-like protein-1(VILIP-1)and chitinase-3-like protein 1(CHI3L1 or YKL-40)in cerebrospinal fluid(CSF)are newly discovered markers indicating neuronal damage and microglial activation,respectively.Phosphorylated tau(p-tau)reflects the neuropathology of Alzheimer’s disease(AD)and is useful as diagnostic markers for AD.However,it is unknown whether these biomarkers have similar or complementary information in AD.Methods:We stratified 121 participants from the Alzheimer’s Disease Neuroimaging Initiative(ADNI)database into cognitively normal(CN),stable mild cognitive impairment(sMCI),progressive MCI(pMCI),and dementia due to AD.Analysis of covariance(ANOVA)and chi-square analyses,Spearman correlation,and logistic regression models were performed to test the demographic,associations between biomarkers,and diagnostic accuracies,respectively.Linear mixed-effects models were used to evaluate the effects of CSF amyloid-β(Aβ)on above biomarkers within diagnostic groups,the combination of diagnostic group and Aβstatus as predictor,and CSF biomarkers as predictors of AD features,including cognition measured by Mini–Mental State Examination(MMSE)and brain structure and white matter hyperintensity(WMH)measured by magnetic resonance imaging(MRI).Results:P-tau,VILIP-1,and YKL-40 were all predictors of AD diagnosis,but combinations of biomarkers did not improve the diagnostic accuracy(AUC 0.924 for p-tau,VILIP-1,and YKL-40)compared to p-tau(AUC 0.922).P-tau and VILIP-1 were highly correlated(r=0.639,p<0.001)and strongly associated with Aβpathology across clinical stages of AD,while YKL-40 was correlated with Aβpathology in CN and AD groups.VILIP-1 was associated with acceleration of cognitive decline,hippocampal atrophy,and expansion of ventricles in longitudinal analyses.YKL-40 was associated with hippocampal atrophy at baseline and follow-up,while p-tau was only associated with worsening WMH at baseline.Conclusions:CSF levels of p-tau,VILIP-1,and YKL-40 may have utility for discriminating between cognitively normal subjects and patients with AD.Increased levels of both VILIP-1 and YKL-40 may be associated with disease degeneration.These CSF biomarkers should be considered for future assessment in the characterization of the natural history of AD. | Hua Zhang Kok Pin Ng Joseph Therriault Min Su Kang Tharick APascoal Pedro Rosa-Neto Serge Gauthier the Alzheimer’s Disease Neuroimaging Initiative | 2018 | Translational Neurodegeneration2018,7,1: | 5 |
| 4 | Associations of AT(N) biomarkers with neuropsychiatric symptoms in prechnical Alzheimer’s disease and cognitively unimpaired individuals显示文摘The development of in vivo biomarkers of Alzheimer's disease(AD)has advanced the diagnosis of AD from a clinical syndrome to a biological construct.The preclinical stage of AD continuum is defined by the identification of AD biomarkers crossing the pathological threshold in cognitively unimpaired individuals.While neuropsychiatric symptoms(NPS)are non-cognitive symptoms that are increasingly recognized as early manifestations of AD,the associations of NPS with AD pathophysiology in preclinical AD remain unclear.Here,we review the associations between NPS and AD biomarkers amyloid-(3(Aβ),tau and neurodegeneration in preclinical AD and cognitivelyunimpaired individuals in 19 eligible English-language publications(8 cross-sectional studies,10 longitudinal,1 both cross-sectional and longitudinal).The cross-sectional studies have consistently shown that NPS,particularly depressive and anxiety symptoms,are associated with higher Aβ.The longitudinal studies have suggested that greater NPS are associated with higher Aβ and cognitive decline in cognitively unimpaired subjects over time.However,most of the studies have either cross-sectionally or longitudinally shown no association between NPS and tau pathology.For the association of NPS and neurodegeneration,two studies have shown that the cerebrospinal fluid total-tau is linked to longitudinal increase in NPS and that the NPS may predict longitudinal metabolic decline in preclinical AD,respectively.However,evidence for the association between atrophy and NPS in preclinical AD is less consistent.Therefore,future longitudinal studies with well-designed methodologies and NPS measurements are required not only to determine the relationship among AT(N)biomarkers,NPS and cognitive decline,but also to elucidate the contribution of comorbid pathology to preclinical AD. | Kok Pin Ng Hui Chiew Pedro Rosa-Neto Nagaendran Kandiah Zahinoor Ismail Serge Gauthier | 2021 | Translational Neurodegeneration2021,10,1: | 2 |
| 5 | Clinical and radiographic subtypes of vascular cognitive impairment in a clinic-based cohort study显示文摘 | Kenneth Rockwood Sandra E. Black Xiaowei Song David B. Hogan Serge Gauthier Chris MacKnight Robert Vandorpe Antonio Guzman Patrick Montgomery Andrew Kertesz Remi W. Bouchard Howard Feldman | 2005 | Journal of the Neurological Sciences2005,,1: | 2 |
| 6 | 阿尔茨海默病现状及展望显示文摘Aging is an undeniable fact of life and the global population is aging to a historically unprecedented degree. The population aged65 years or older comprises 750 million people, representing nearly 10%of the global population. As a result of prolonged life expectancy and falling mortality rates, China has become one of the most rapidly aging countries in the world, even surpassing several high-income countries in North America and Europe. | 刘文颖 Serge Gauthier 贾建平 | 2022 | Science Bulletin2022,67,24: | 1 |
| 7 | Mild cognitive impairment显示文摘 | Serge Gauthier Barry Reisberg Michael Zaudig Ronald C Petersen Karen Ritchie Karl Broich Sylvie Belleville Henry Brodaty David Bennett Howard Chertkow Jeffrey L Cummings Mony de Leon Howard Feldman Mary Ganguli Harald Hampel Philip Scheltens Mary C Tierne | 2006 | The Lancet . 2006 (9518)2006,,: | 1 |
| 8 | Prevention strategies for Alzheimer’s disease显示文摘Symptomatic treatment during the dementia stage of Alzheimer’s disease(AD)cannot delay or halt the progression of this disease.Therefore,prevention in the preclinical stage is likely the most effective way to decrease the incidence of this age-associated neurodegenerative condition,and its associated burden for individuals and society.Age,gender,family history,ApoE4,systolic blood pressure,body mass index,total cholesterol level and physical activity are all used as component of dementia risk score.There have been numerous challenges in conducting primary prevention trials in AD.Enrichment strategies for prevention studies include studying those subjects with more risk factors for AD,such as older age,those with a positive family history of late onset AD,and those who are ApoE4 positive.Each of these strategies is designed to increase the probability of developing AD thereby decreasing the sample size or the duration of follow up.Another strategy would be to target directly the pathophysiology of AD in its preclinical stages and use the biomarkers in prevention trial as surrogate markers.This will be done first in carriers of dominantly inherited early onset AD.As this research takes place networks of memory clinics must prepare to transfer new knowledge to persons interested in a preventive approach to AD. | Serge Gauthier Liyong Wu Pedro Rosa-Neto Jianping Jia | 2012 | Translational Neurodegeneration2012,1,1: | 1 |
| 9 | Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS–ADRDA criteria显示文摘 | Bruno Dubois Howard H Feldman Claudia Jacova Steven T DeKosky Pascale Barberger-Gateau Jeffrey Cummings André Delacourte Douglas Galasko Serge Gauthier Gregory Jicha Kenichi Meguro John O’Brien Florence Pasquier Philippe Robert Martin Rossor Steven Sallow | 2007 | Lancet Neurology2007,,: | 1 |
| 10 | Mild cognitive impairment显示文摘 | Serge Gauthier Barry Reisberg Michael Zaudig Ronald C Petersen Karen Ritchie Karl Broich Sylvie Belleville Henry Brodaty David Bennett Howard Chertkow Jeffrey L Cummings Mony de Leon Howard Feldman Mary Ganguli Harald Hampel Philip Scheltens Mary C Tierne | 2006 | The Lancet2006,,9518: | 1 |
| 11 | Vascular cognitive impairment显示文摘 | John T O’Brien Timo Erkinjuntti Barry Reisberg Gustavo Roman Tohru Sawada Leonardo Pantoni John V Bowler Clive Ballard Charles DeCarli Philip B Gorelick Kenneth Rockwood Alistair Burns Serge Gauthier Steven T DeKosky | 2003 | Lancet Neurology2003,,2: | 1 |
| 12 | Mild cognitive impairment显示文摘 | Serge Gauthier Barry Reisberg Michael Zaudig Ronald C Petersen Karen Ritchie Karl Broich Sylvie Belleville Henry Brodaty David Bennett Howard Chertkow Jeffrey L Cummings Mony de Leon Howard Feldman Mary Ganguli Harald Hampel Philip Scheltens Mary C Tierne | 2006 | 2006 (9518)2006,,9518: | 1 |
| 13 | Alzheimer's disease 显示文摘 | Clive Ballard Mycpsych Serge Gauthier Anne Corbett | 2011 | Lancet2011,377,9770: | 1 |
| 14 | Executive dysfunction in vascular cognitive impairment in the consortium to investigate vascular impairment of cognition study显示文摘 | Paige Moorhouse Xiaowei Song Kenneth Rockwood Sandra Black Andrew Kertesz Serge Gauthier Howard Feldman | 2009 | Journal of the Neurological Sciences2009,,1: | 1 |
| 15 | Vascular cognitive impairment显示文摘 | John T O’Brien Timo Erkinjuntti Barry Reisberg Gustavo Roman Tohru Sawada Leonardo Pantoni John V Bowler Clive Ballard Charles DeCarli Philip B Gorelick Kenneth Rockwood Alistair Burns Serge Gauthier Steven T DeKosky | 2003 | Lancet Neurology2003,,2: | 1 |
| 16 | Emerging Therapies for Vascular Dementia and Vascular Cognitive Impairment显示文摘 | Timo Erkinjuntti Gustavo Román Serge Gauthier Howard Feldman Kenneth Rockwood Marc Fisher | 2004 | Stroke: Journal of the American Heart Association2004,,: | 1 |
| 17 | Treatment of vascular dementia-evidence from clinical trials with cholinesterase inhibitors显示文摘 | Timo Erkinjuntti Gustavo Roman Serge Gauthier | 2004 | Neurolo Sci2004,,: | 1 |
| 18 | The concept of vascular cognitive impairment显示文摘 | Timo Erkinjuntti Serge Gauthier | 2009 | Front Neurol Neurosci2009,24,: | 1 |
| 19 | Perspectives on a collaborative Canada-China research program on diagnostic biomarkers for pre-dementia stages of Alzheimer’s disease显示文摘 | Serge Gauthier Jianping Jia Sylvie Belleville Simon Cloutier Dessa Sadovnick Colleen Guimond Laura Robb Mario Masellis Guy A Rouleau Liyong Wu Pedro Rosa-Neto | 2017 | Journal of Translational Neuroscience2017,2,3: | 0 |
| 20 | Neuropsychiatric symptoms are early indicators of an upcoming metabolic decline in Alzheimer's disease显示文摘Background:Neuropsychiatric symptoms(NPS)are increasingly recognized as early non-cognitive manifestations in the Alzheimer's disease(AD)continuum.However,the role of NPS as an early marker of pathophysiological progression in AD remains unclear.Dominantly inherited AD(DIAD)mutation carriers are young individuals who are destined to develop AD in future due to the full penetrance of the genetic mutation.Hence,the study of DIAD mutation carriers enables the evaluation of the associations between pure AD pathophysiology and metabolic correlates of NPS without the confounding effects of co-existing pathologies.In this longitudinal study,we aimed to identify regional brain metabolic dysfunctions associated with NPS in cognitively intact DIAD mutation carriers.Methods:We stratified 221 cognitively intact participants from the Dominantly Inherited Alzheimer's Network according to their mutation carrier status.The interactions of NPS measured by the Neuropsychiatric Inventory-Questionnaire(NPI-Q),age,and estimated years to symptom onset(EYO)as a function of metabolism measured by[^(18)F]flurodeoxyglucose([^(18)F]FDG)positron emission tomography,were evaluated by the mixed-effects regression model with family-level random effects in DIAD mutation carriers and non-carriers.Exploratory factor analysis was performed to identify the neuropsychiatric subsyndromes in DIAD mutation carriers using the NPI-Q subcomponents.Then the effects of interactions between specific neuropsychiatric subsyndromes and EYO on metabolism were evaluated with the mixed-effects regression model.Results:A total of 119 mutation carriers and 102 non-carriers were studied.The interaction of higher NPI-Q and shorter EYO was associated with more rapid declines of global and regional[18F]FDG uptake in the posterior cingulate and ventromedial prefrontal cortices,the bilateral parietal lobes and the right insula in DIAD mutation carriers.The neuropsychiatric subsyndromes of agitation,disinhibition,irritability and depression interacted with the EYO to drive the[^(18)F]FDG uptake decline in the DIAD mutation carriers.The interaction of NPI and EYO was not associated with[^(18)F]FDG uptake in DIAD mutation non-carriers.Conclusions:The NPS in cognitively intact DIAD mutation carriers may be a clinical indicator of subsequent metabolic decline in brain networks vulnerable to AD,which supports the emerging conceptual framework that NPS represent early manifestations of neuronal injury in AD.Further studies using different methodological approaches to identify NPS in predinical AD are needed to validate our findings. | Kok Pin Ng Tharick A.Pascoal Sulantha Mathotaarachchi Yiong Huak Chan Lai Jiang Joseph Therriault Andrea L.Benedet Monica Shin Nagaendran Kandiah Celia M.T.Greenwood Pedro Rosa-Neto Serge Gauthier Dominantly Inherited Alzheimer Network | 2021 | Translational Neurodegeneration2021,10,1: | 0 |